GlassScriptPhysician profile
Karin R Brimhall
NPI 1255578126
$11,903.76
in general payments reported to CMS, 2019-2025
30 companies · $2,678 in 2025
The $2,678 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,912 · 2022: $2,686 · 2023: $2,391 · 2024: $2,236 · 2025: $2,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,007 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,007.19 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,507.66 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,251.67 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $1,057.36 | 2021-2025 | Dupixent, Libtayo |
| Epi Health, LLC | $987.25 | 2022 | |
| Amgen INC. | $903.56 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $881.90 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $846.09 | 2021-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $800.92 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $485.40 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $445.46 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Almirall LLC | $425.63 | 2021-2023 | Klisyri |
| Pfizer INC. | $366.49 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $349.79 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.97 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $301.42 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $170.41 | 2023-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $130.13 | 2021-2025 | |
| Dermavant Sciences, INC. | $127.31 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $124.98 | 2022 | |
| Hill Dermaceuticals, INC. | $78.07 | 2025 | Tolak |
| Mayne Pharma Commercial LLC | $74.08 | 2021-2025 | |
| Organon LLC | $53.14 | 2025 | Nexplanon, Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.01 | 2021-2022 | |
| Springworks Therapeutics, INC. | $41.38 | 2025 | Gomekli |
| Boston Scientific Corporation | $36.18 | 2022-2023 | Solyx Sis System |
| Kyowa Kirin, INC. | $24.62 | 2025 | |
| Dermira, INC. | $21.98 | 2021 | |
| Biofrontera INC. | $19.38 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $16.49 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Brimhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.